Schwab US Dividend Equity ETF Sees Inflows Amid Weekly Decline

Schwab US Dividend Equity ETF ( $SCHD ) has fallen by 1.08% in the past week. It has experienced a 5-day net inflow of $1.41 billion.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:

• Amgen Inc continued to spotlight its late‑stage pipeline this week, outlining progress on several key clinical programs that could reshape its long‑term growth profile. The company is moving a Phase 3 study of olpasiran into the start‑up phase, targeting patients with established cardiovascular disease and elevated lipoprotein(a); if the injectable drug can safely shrink soft plaque in coronary arteries as hoped, it could open a premium cardiovascular niche currently underserved by standard cholesterol therapies. In parallel, Amgen is advancing maridebart cafraglutide across obesity‑related indications: a Phase 3 trial will test whether the drug can improve outcomes for overweight or obese adults with obstructive sleep apnea on positive airway pressure therapy, while a separate Phase 1 QT study is assessing its cardiac safety in people with obesity. On the sentiment side, Wall Street remains cautiously constructive, with Truist Financial and Wells Fargo both reiterating Hold ratings around the low‑to‑mid $300s and the broader analyst community calling the stock a Moderate Buy with mid‑single‑digit upside potential, suggesting investors are watching these pipeline catalysts more closely than near‑term earnings.
• Merck & Company did not feature in the latest batch of company‑specific updates, leaving investors with no fresh trial, product, or guidance news to reassess its outlook. In the absence of new developments, sentiment around the stock is likely to continue tracking broader pharma trends and expectations for its existing oncology and vaccine franchises rather than any new near‑term catalysts.
• Cisco was also absent from this week’s major announcements, with no notable disclosures on orders, AI‑driven networking demand, or capital‑return moves to move the stock. Without incremental information, investors in Cisco will be focused on macro tech spending patterns and the company’s ongoing shift toward software and recurring revenue while they await the next scheduled update.